References
- European Association for the Study of the Liver, European Organisation for Research and Treatement of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43. 10.1016/j.jhep.2011.12.001
- Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33: 41–52. 10.1007/s00270-009-9711-719908093
- Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS, et al. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol 2010; 101: 476-80. 10.1002/jso.2152220213741
- Malagari K, Pomoni M, Moschouris H, Bouma E, Koskinas J, Stefaniotou A, et al. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc Intervent Radiol 2012; 35: 1119-28.10.1007/s00270-012-0394-022614031
- Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46: 474-81.1723948010.1016/j.jhep.2006.10.020
- Popovic P, Stabuc B, Jansa R, Garbajs M. Survival of patients with intermediate stage hepatocellular carcinoma treated with superselective transarterial chemoembolization using doxorubicin-loaded DC Bead under conebeam computed tomography control. Radiol Oncol 2016; 50: 418-26. 10.1515/raon-2015-0045
- Kettenbach J, Stadler A, Katzler IV, Schernthaner R, Blum M, Lammer J, et al. Drug-loaded microspheres for the treatment of liver cancer: review of current results. Cardiovasc Intervent Radiol 2008; 31: 468-76. 10.1007/s00270-007-9280-618228095
- Malgari K, Chatzimichael K, Alexopöulou E, Kelekis A, Hall B, Dourakis S, et al. Transarterial chemoembolisation of unresectable hepatocelular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Interv Radiol 2008; 31: 269-80.10.1007/s00270-007-9226-z
- Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Sem Liver Disease 2010; 30: 52-60. 10.1055/s-0030-1247132
- Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429-42.1254079410.1053/jhep.2003.50047
- Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131: 461-9.1689060010.1053/j.gastro.2006.05.021
- Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, Tremosini S, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol 2012; 56: 1330-5. 10.1016/j.jhep.2012.01.00822314428
- Fatourou EM, Tsochatzis EA. ART and science in using transarterial chemoembolization for retreating patients with hepatocellular carcinoma. Hepatobiliary Surg Nutr 2014; 3: 415-8. 10.3978/j.issn.2304-3881.2014.07.0125568865
- Tsochatzis EA, Fatourou E, O’Beirne J, Meyer T, Burroughs AK. Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. World J Gastroenterol 2014; 20: 3069-77. 10.3748/wjg.v20.i12.306924695579
- Yang HF, Du Y, Ni JX, Zhou XP, Li JD, Zhang Q, et al. Perfusion computed tomography evaluation of angiogenesis in liver cancer. Eur Radiol 2010; 20: 1424-30. 10.1007/s00330-009-1693-y20179942
- Morsbach F, Pfammatter T, Reiner CS, Fischer MA, Sah BR, Winklhofer S, et al. Computed tomographic perfusion imaging for the prediction of response and survival to transarterial radioembolization of liver metastases. Invest Radiol 2013; 48: 787-94. 10.1097/RLI.0b013e31829810f723748229
- Blomley MJ, Coulden R, Dawson P, Kormano M, Donlan P, Bufkin C, et al. Liver perfusion studied with ultrafast CT. J Comput Assist Tomogr 1995; 19: 424-33.779055310.1097/00004728-199505000-00016
- Garcia-Figueiras R, Goh VJ, Padhani AR, Baleato-González S, Garrido M, León L, et al. Ct perfusion in oncologic imaging: A useful tool? AJR Am J Roentgenol 2013; 200: 8-19. 10.2214/AJR.11.847623255736
- Avsenik J, Bisdas S, Popovic KS. Blood-brain barrier permeability imaging using perfusion computed tomography. Radiol Oncol 2015; 49: 107-14. 10.2478/raon-2014-002926029020
- Goh V, Halligan S, Daley F, Wellsted DM, Guenther T, Bartram CI. Colorectal tumor vascularity: quantitative assessment with multidetector CT--do tumor perfusion measurements reflect angiogenesis? Radiology 2009; 249: 510-7. 10.1148/radiol.2492071365
- Tsushima Y, Funabasama S, Aoki J, Sanada S, Endo K. Quantitative perfusion map of malignant liver tumors, created from dynamic computed tomography data. Acad Radiol 2004; 11: 215-23.1497459710.1016/S1076-6332(03)00578-6
- Yang L, Zhang XM, Tan BX, Liu M, Dong GL, Zhai ZH. Computed tomographic perfusion imaging for the therapeutic response of chemoembolization for hepatocellular carcinoma. J Comput Assist Tomogr 2012; 36: 226-30. 10.1097/RCT.0b013e318245c23c22446364
- Chen G, Ma DQ, He W, Zhang BF, Zhao LQ. Computed tomography perfusion in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2008; 14: 5738-43.10.3748/wjg.14.573818837093
- Sahani D, Holalkere DS, Mueller PR, Zhu AX. Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue-initial experience. Radiology 2007; 243: 736-43.10.1148/radiol.243305202017517931
- Zhou ZF, Huang HL, Xu B, et al. Clinic application with MSCT perfusion in liver tumor. Linchuang Fangshexue Zazhi 2006; 25: 233-7.
- Komemushi A, Tanigawa N, Kojima H, Kariya S, Sawada S. CT perfusion of the liver during selective hepatic arteriography: pure arterial blood perfusion of liver tumor and parenchyma. Radiat Med 2003; 21: 246-51.14743897
- Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011; 8: 210-21. 10.1038/nrclinonc.2011.2121364524
- De Robertis R, Tinazzi Martini P, Demozzi E, Puntel G, Ortolani S, Cingarlini S, et al. Prognostication and response assessment in liver and pancreatic tumors: the new imaging. World J Gastroenterol 2015; 21: 6794-808. 10.3748/wjg.v21.i22.679426078555
- Ash L, Teknos TN, Gandhi D, Patel S, Mukherji SK. Head and neck squamous cell carcinoma: CT perfusion can help noninvasively predict intratumoral microvessel density. Radiology 2009; 251: 422-8. 10.1148/radiol.251208074319276321
- Chen Y, Zhang J, Dai J, Feng X, Lu H, Zhou C. Angiogenesis of renal cell carcinoma: perfusion CT findings. Abdom Imaging 2010; 35: 622-8. 10.1007/s00261-009-9565-019763683
- D’Assignies G, Couvelard A, Bahrami S, Vullierme MP, Hammel P, Hentic O, et al. Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors. Radiology 2009; 250: 407-16. 10.1148/radiol.250108029119095784
- Fournier LS, Oudard S, Thiam R, Trinquart L, Banu E, Medioni J, et al. Metastatic renal carcinoma: evaluation of anti-angiogenic therapy with dynamic contrast enhanced CT. Radiology 2010; 256: 511-8. 10.1148/radiol.10091362
- Bellomi M, Petralia G, Sonzogni A, Zampino MG, Rocca A. CT perfusion for the monitoring of neo-adjuvant chemoradiation therapy in rectal carcinoma. Radiology 2007; 244: 486-93.10.1148/radiol.2442061189
- Han KS, Jung DC, Choi HJ, Jeong MS, Cho KS, Joung JY, et al. Pretreatment assesment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy. Cancer 2010; 116: 2332-42. 10.1002/cncr.25019
- Bisdas S, Surlan-Popovic K, Didanovic V, Vogl TJ. Functional CT of squamous cell carcinoma in the head and neck: repeatability of tumor and muscle quantitative measurements, inter- and intra-observer agreement. Eur Radiol 2008; 18: 2241-5. 10.1007/s00330-008-0990-118446342
- Gandhi D, Chepeha DB, Miller T, Carlos RC, Bradford CR, Karamchandani R, et al. Correlation between initial and early follow-up CT perfusion parameters with endoscopic tumor response in patients with advanced squamous cell carcinomas of the oropharynx treated with organ-preservation therapy. AJNR Am J Neuroradiol 2006; 27: 101–6.16418366
- Surlan-Popovic K, Bisdas S, Rumboldt Z, Koh TS, Strojan P. Changes in perfusion CT of advanced squamous cell carcinoma of the head and neck treated during the course of concomitant chemoradiotherapy. AJNR Am J Neuroradiol 2010; 31: 570-5. 10.3174/ajnr.A185919875475
- Wang J, Wu N, Cham MD, Song Y. Tumor response in patients with advanced non-small cell lung cancer: perfusion CT evaluation of chemotherapy and radiation therapy. AJR 2009; 193: 1090-6. 10.2214/AJR.08.1367
- Jiang T, Kambadakone A, Kulkarni NM, Zhu AX, Sahani DV. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). Invest Radiol 2012; 47: 11-7. 10.1097/RLI.0b013e3182199bb521512396
- Petralia G, Fazio N, Bonello L, D’Andrea G, Radice D, Bellomi M. Perfusion computed tomography in patients with hepatocellular carcinoma treated with thalidomide: initial experience. J Comput Assist Tomogr 2011; 35: 195–201. 10.1097/RCT.0b013e31820ccf5121412089
- Michielsen K, De Keyzer F, Verslype C, Dymarkowski S, van Malenstein H, Oyen R, et al. Pretreatment DCE-MRI for prediction of PFS in patients with inoperable HCC treated with TACE. Cancer Imaging 2011; 11: 114.10.1102/1470-7330.2011.9058
- Visualization of multistep hepatocarcinogenesis using various imaging biomarkers [internet]. ECR 2014. C-0120. Retrieved from: http://posterng.netkey.at/esr/viewing/index.php?module=viewing_poster&task=viewsection&pi=119549&ti=394293&searchkey=
- Ippolito D, Capraro C, Casiraghi A, Cestari C, Sironi S. Quantitative assessment of tumour associated neovascularisation in patients with liver cirrhosis and hepatocellular carcinoma: role of dynamic-CT perfusion imaging. Eur Radiol 2012; 22: 803-11. 10.1007/s00330-011-2307-z22086560
- Sahani DV, Holalkere NS, Mueller PR, Zhu AX. Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue--initial experience. Radiology 2007; 243: 736-43.10.1148/radiol.243305202017517931
- Frampas E, Lassau N, Zappa M, Vullierme MP, Koscielny S, Vilgrain V. Advanced hepatocellular carcinoma: early evaluation of response to targeted therapy and prognostic value of perfusion CT and dynamic contrast enhanced-ultrasound. Preliminary results. Eur J Radiol 2013; 82: 205-11. 10.1016/j.ejrad.2012.12.004
- Schmitz S, Rommel D, Michoux N, Lhommel R, Hanin FX, Duprez T, et al. Dynamic contrast-enhanced computed tomography to assess early activity of cetuximab in squamous cell carcinoma of the head and neck. Radiol Oncol 2015; 49: 17-25. 10.2478/raon-2014-003025810697
- Kim SH, Kamaya A, Willmann JK. CT perfusion of the liver: principles and applications in oncology. Radiology 2014; 272: 322-44. 10.1148/radiol.1413009125058132
- Mazzei MA, Preda L, Cianfoni A, Volterrani L. CT Perfusion: Technical developments and current and future applications. Biomed Res Int 2015; 2015: 397521. 10.1155/2015/39752125695071